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Introduction
Adverse drug reactions (ADRs) are a relevant problem in health 
care, and particularly in the hospital setting [1-3]. Unfortunately, 
ADRs are underreported in general [4], and particularly in hospitals 
[5]. Knowledge and attitudes of health professionals appear to be 
strongly associated with underreporting in a high proportion of studies 
[6]. Therefore, it is important to know the opinions, perceptions 
and attitudes of hospital doctors with respect to ADRs because 
their knowledge can help to improve the spontaneous reporting of 
ADRs. Several studies have assessed the knowledge, behaviour and 
attitudes of physicians regarding ADRs and their reporting to the 
pharmacovigilance systems [7-14]. Nevertheless, those studies have 
not evaluated specifically the doubts, uncertainties, misunderstandings 
and misconceptions that medical doctors may have about ADRs and 
pharmacovigilance systems, which are barriers to the development 
of pharmacovigilance activities. Thus, the objective of our study was 
to analyze the opinions and doubts that hospital doctors have about 
ADRs and pharmacovigilance activities. 
Methods
A survey was carried out in a tertiary university hospital. The 
design of the study was qualitative because this type of methodological 
research allows us to understand the perceptions of doctors adequately. 
The qualitative technique used in the study was the focus group 
discussion methodology [15]. Participants were selected using a 
theoretical sampling model. Focus group discussions were carried 
out among physicians (house staff and residents in training) from 
different medical specialties. The groups were naturally occurring 
using pre-existing groups of people who worked together in the 
same medical department of the hospital. Thirteen focus group non-
structured discussions were conducted and 296 physicians (each 
focus group had approximately 22 participants) from the following 
medical specialities participated: Anaesthesiology, Cardiology, 
Dermatology, Endocrinology, Gastroenterology, Infectious diseases, 
Internal medicine, Intensive care medicine, Nephrology, Pneumology, 
Neurology, Psychiatry, and Rheumatology. 
Focus groups were held from January 2008 to December 2013, and 
the running of the groups took place in the annual pharmacovigilance 
sessions in each of the departments of the medical specialities described 
above. These sessions lasted from 45 to 60 minutes in which the 
pharmacovigilance program of the hospital was introduced. In the 
first part of the sessions, the global results of the program and the 
specific results relating to each medical department were presented 
by a clinical pharmacologist specialised in pharmacovigilance. News 
and other topics to do with pharmacovigilance were also introduced. 
In the second part of the sessions, the participants were encouraged 
to share their points of view and doubts about the different aspects 
of ADRs and pharmacovigilance activities, and an open discussion 
was held. The participants were told that the purpose of the sessions 
was to explain pharmacovigilance activities, as well as to understand 
their perception and doubts about ADRs and pharmacovigilance. 
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Abstract
Purpose: The aim of the study was to evaluate the opinions and concerns of hospital doctors about adverse 
drug reactions (ADRs) and pharmacovigilance.
Methods: A qualitative study was undertaken using focus groups in sessions on pharmacovigilance activities 
conducted in thirteen clinical services of a tertiary university hospital. A total of 296 physicians participated in these 
sessions by giving their opinions or expressing their doubts about ADR and pharmacovigilance activities which were 
recorded by different observers and subsequently analysed.
Results: Doctors remarked on: a) the importance, concern, frequency and specific types of ADRs that were 
observed in clinical practice; b) problems of clinical decision making related to the suspected ADRs; c) methods for 
improving detection and reporting ADRs; d) monitoring of specific ADRs or ADRs caused by specific drugs; e) and 
measures to prevent and minimize the risk of ADRs. Physicians expressed doubts related to: a) the basic concepts of 
ADRs; b) the methods of ADR identification and evaluation; c) the objectives and procedures of pharmacovigilance 
programmes; d) and the impact of pharmacovigilance activities.
Conclusions: Hospital doctors believe that ADRs are a matter for concern in their daily clinical practice, and 
monitoring ADRs as well as measures for preventing the risk of ADRs are needed. Nevertheless, doctors have 
doubts about what an ADR is, the accuracy of diagnostic methods, the development of pharmacovigilance activities 
and their impact on clinical practice. Pharmacovigilance should be better explained through a continuous feedback 
and close relationship with hospital doctors. 
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A pharmacologist acted as the moderator, and encouraged the 
participants to discuss the topic and guided the discussion. Another 
clinical pharmacologist, acting as an independent observer, took notes 
on the subjects that emerged from the discussion in each session. These 
notes were contrasted with other clinical pharmacologists, who also 
attended the sessions. A coding method and framework analysis with 
the data collected was performed (transcription, familiarisation with 
the interview, coding, developing a working analytical framework, 
applying the analytical framework, charting data into the framework 
matrix, interpreting the data) [16].
Results 
An overview of the issues identified in the sessions are shown in 
(Tables 1 (points of view) and 2 (doubts)). 
Opinions
Impact of ADRs on clinical practice: Doctors often stated that 
ADRs were important in their experience from a clinical perspective 
in terms of concerns, frequency, and clinical consequences. For 
instance, one doctor said, “One situation that worried us is mandibular 
osteonecrosis produced by bisphosphonates because we often prescribe 
these drugs”. In addition, doctors usually talked about characteristics of 
ADRs seen in their practice with particular emphasis on the drugs most 
used in their area of clinical expertise. For example, another doctor 
said, “We often see adverse effects as renal dysfunction produced by 
angiotensin converting enzyme (ACE) inhibitors or angiotensin II 
receptor antagonists and diuretics, generally in elderly patients with 
risk factors such as diarrhoea or dehydration”. Another physician 
said, “We see cases of pathological gambling in patients treated with 
dopamine agonists”. Doctors reported many other cases of ADRs, 
relating to a specific drug or a pharmacological group, which were 
identified in their clinical practice.
Problems of diagnosing ADR: Doctors also explained they 
frequently had problems taking clinical decisions on causation 
related to clinical situations with adverse events and with drugs that 
were suspected of causing those events. For instance, one physician 
revealed, “In hospitalised patients with hepatic enzymes abnormalities 
and thrombocytopenia, we have problems in the differential diagnosis 
when we suspect the implication of medicines”. Another physician said, 
“We sometimes have difficulties to establish a causality relationship 
between some conditions, such as infections or progressive multifocal 
leukoencephalopathy, and immunosuppressive drugs”. This problem 
was more serious when patients were treated with multiple medicines. 
One doctor said, “It is difficult to know whether adverse events are due 
to a specific drug, especially when patients are treated with multiple 
drugs”.
Measures for improving detection and reporting ADRs: Doctors 
also gave their personal opinions about methods to improve ADR 
reporting and detection in the hospital based on their own clinical 
experience. For example, one physician said, “ADRs in the hospital 
could be reported clicking on specific tabs in the electronic medical 
records”. Alternative methods for identifying ADRs were proposed by 
hospital doctors. Another doctor said, “It might be useful to identify 
ADRs occurring in the hospital through reviewing hospital discharge 
reports”. 
Monitoring of particular ADRs produced by specific medicines: 
Doctors made contributions about the importance of monitoring 
particular ADRs produced by specific groups of medicines, especially 
those related to their own clinical areas or with new marketed medicines 
that have new mechanisms of action and following up patients treated 
with those drugs. For example one of them said, “Each time it is more 
typical to use medicines with new mechanisms of action such as 
medicines that inhibit TNF-α factor. It would be very useful to do a 
follow-up on these medicines especially on everything that it is related 
to the safety of these drugs in clinical practice”. 
Measures to prevent and minimize ADRs in the hospital: The 
doctors were concerned that very often a lot of patients, especially 
the elderly, are polymedicated with several drugs that they do not 
really need. Hence, they proposed checking these prescriptions and 
withdrawing the unnecessary medicines. One doctor noted, “We 
frequently see polymedicated patients. It would be worthwhile checking 
all the medicines that patients are being treated with and withdrawing 
those ones that the patient does not need”. Doctors also suggested 
avoiding some drugs in patients who had risk factors for developing 
specific ADRs. For instance, one doctor said, “We should avoid using 
nonsteroidal anti-inflammatory drugs in patients with impaired 
renal function”. Another doctor underlined the importance of using 
additional tests in order to prevent or reduce ADRs. For example, one 
doctor said, “It might be very useful to monitor plasma concentrations 
of antiretroviral medicines with the purpose of better adjusting the 
dose, and thus avoiding ADRs”. 
Doubts
Doubts about the concept of ADRs: Physicians still have many 
doubts about what ADRs are. For example, one doctor asked, “What is 
an ADR?” Another doctor asked, “Can we consider the effects derived 
from the mechanism of action of the medicine as an ADR?” Doctors 
also have doubts about specific aspects related to ADRs, such as the 
severity. For instance, one doctor asked, “What does a serious ADR 
mean?”.
1. Impact of ADRs on hospital doctors’ clinical practice
ADRs concern hospital doctors
ADRs are very frequent in the experience of hospital doctors
ADRs have important clinical consequences
ADRs are usually specific depending on the clinical speciality
2. Problems of hospital doctors in diagnosing ADRs
Difficulties with clinical decisions relating to ADRs
Difficulties with patients treated with several drugs
3. Methods for improving detection and reporting ADRs
Reporting ADRs using electronic medical records
Review of hospital discharge reports 
4. Monitoring of specific ADRs produced by specific medicines
Follow up of patients treated with specific groups of medicines
Follow up of patients treated with medicines with new mechanisms of action
5. Measures to prevent and minimise ADRs in hospital
Review of prescribed drugs in patients with polypharmacy
Avoiding specific groups of drugs in patients with risk factors
Testing for pharmacological parameters
Table 1: Hospital doctors’ opinions on pharmacovigilance activities.
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Doubts about the methods of identification and evaluation of 
ADRs: Doctors had doubts about the how to identify and evaluate ADRs 
within the context of pharmacovigilance activities. Thus, the physicians 
asked several questions related to the process of identification and 
evaluation of ADRs, “How are ADRs identified?”, “Who makes the 
evaluation?”, “How are the cases of suspected ADRs evaluated?”, “How 
is the casual relationship between ADRs and medicines established?”. 
In addition, doctors were uncertain about the true causal relationship 
between adverse events and several groups of drugs or specific drugs, 
which have recently been reported on in medical journals.
Doubts about the objectives, and procedures of 
pharmacovigilance programmes: The participants frequently asked 
questions about the pharmacovigilance programmes because they did 
not know how our hospital pharmacovigilance programme and the 
Spanish System of Pharmacovigilance work. For example, they asked 
several questions such as, “Who has to send the yellow cards when ADRs 
are suspected?”, “Where are these yellow cards to be sent?”, “Should 
all ADRs be reported, even though they are very well-known ADRs?”, 
“Should cases of ADRs in patients treated with multiple medicines be 
reported, when it is very difficult to know what the causative medicine 
is?”, “What is the procedure to identify diagnoses related to ADRs in 
the hospital?”, “How do you establish a causal link between a drug and 
an adverse event?” .
Doubts about the impact of pharmacovigilance activities: 
Clinicians had doubts about the usefulness and impact of 
pharmacovigilance activities on patients’ safety. The doctors had 
several doubts about the decision-making process relating to drug use 
and public health. Thus, some clinicians asked several questions on 
these topics, such as “Does the information in cases of suspected ADRs 
go on the drug information sheet?”, “How is the information added or 
changed on safety on the drug data sheet?, “How are decisions taken 
when a medicine is withdrawn from the pharmaceutical market?”, 
“How useful are the warnings on drug safety?”, “How are the warnings 
about drug safety followed up on?”, “How could pharmacovigilance 
activities prevent ADRs?.
Discussion
Our study has identified the key opinions and doubts that hospital 
physicians have on issues relating to ADRs and pharmacovigilance, 
which are relevant to the development of pharmacovigilance activities. 
It should be noted that pharmacovigilance activities in hospitals 
identify serious ADRs resulting in hospitalisation, and there are ADRs 
occurring in hospitalised patients, often with a high comorbidity, after 
they have received drugs that are only administered in this setting 
[17]. It is noteworthy that analysing the views and doubts of hospital 
physicians is important because they are less likely to report ADRs [5].
The results of this study show that hospital physicians have 
positive opinions and attitudes about pharmacovigilance, and they 
usually consider that pharmacovigilance activities and the reporting 
of ADRs are an important part of good clinical practice. This attitude 
is probably related to the perception of the relevant impact of ADRs 
on clinical practice. However, in spite of this fact several studies have 
shown unsatisfactory levels of knowledge of ADRs among hospital 
doctors [18-21]. Different studies consistently indicate there is still 
an underreporting culture of ADRs among clinical practitioners [4]. 
Moreover, accumulating evidence suggests that doctors’  attitudes 
to their national pharmacovigilance schemes significantly influence 
reporting rates and attitudes vary substantially between countries [9]. 
Variations can be explained by looking at economic and social factors. 
For example, high income countries have the highest ADR reporting 
rates and low income countries the lowest, even though large variations 
across countries in each group have also been reported [22]. Other 
studies have also assessed the opinions, attitudes and knowledge of 
pharmacovigilance among other health professions like nurses and 
pharmacists in hospitals [23,24]. These health professionals also have 
a very positive opinion about pharmacovigilance activities, as well as 
optimal attitudes, but they also underreport ADRs. 
This study also focused on evaluating doubts clinicians had. 
Doctors asked different types of questions about pharmacovigilance 
activities, as well as about several aspects relating to ADRs that they 
usually encountered in their own clinical practice. The doubts and 
misconceptions doctors had about ADRs and pharmacovigilance 
activities could play an important role in explaining the underreporting 
of ADRs. It is important to note that, surprisingly, physicians’ doubts 
and misconceptions on the meaning of ADR were revealed. There are 
doctors who believe that the effects related to the mechanism of action 
of drugs are not ADRs, and only unexpected effects are ADRs. This 
finding is extremely important because the interpretation of the term 
ADR is a key factor influencing the results of surveys on ADRs [17].
Hospital doctors also expressed doubts on accurate methods 
for diagnosing ADRs. Previous studies have already reported on the 
misconception  that absolute confidence in the diagnosis of an  ADR 
is important in deciding whether to report a case [8]. Differential 
diagnosis of ADRs is a difficult and complex process because for each 
adverse event there are many possible causes either pharmacological or 
non-pharmacological. Hence, doctors assessing ADRs face the need to 
make causality assessment judgements on drug-related events. Several 
methods for assessing causality of ADRs have been proposed that can 
be classified into three broad categories: 1) expert judgement, also 
called global introspection; 2) algorithms; 3) and probabilistic methods 
such as Bayesian approaches [25-30]. However, as a result of problems 
of validity and reproducibility, none of the diagnostic methods are 
completely satisfactory. There is still no method universally accepted 
for causality assessment of ADRs. Obviously, there is a need to find 
1. Doubts related to the basic concepts of ADRs
Meaning of ADR
ADRs directly derived from the mechanisms of action of medicines
Severity criteria of ADRs
2. Doubts about the methods of ADR identification and evaluation
Methods of ADR identification
Methods of evaluation of medicine causality
3. Doubts about objectives and procedures of the Pharmacovigilance programmes
Objectives of the Pharmacovigilance programmes
Operational procedures of the Pharmacovigilance programmes
4. Doubts about the impact of the Pharmacovigilance activities
Usefulness of the Pharmacovigilance activities
Effect on patient safety and the safe use of drugs
Decision-making process on the use of drugs relating to public health
Table 2: Hospital doctors’ doubts about the pharmacovigilance activities.
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better procedures to assess ADRs. Doctors also raised questions 
and doubts about national and international systems of reporting 
ADRs, as well as the final impact and effects of pharmacovigilance 
activities. Several studies have also shown that doctors are not aware 
of pharmacovigilance activities and the national system of reporting 
ADRs [12,19,20,31]. It is very important to resolve these doubts because 
the involvement and participation of doctors in pharmacovigilance 
activities may be negatively affected if the goal and the real impact of 
these activities in their clinical practice are unclear to them.
There are different reasons for these doubts and lack of adequate 
knowledge about ADRs and pharmacovigilance activities, such 
as insufficient teaching of pharmacovigilance in the training of 
undergraduate and graduate students, and lack of updating courses 
on pharmacovigilance for health professionals. Education and training 
are the most recognised means of improving ADR reporting [18, 
32]. Continuous medical education, training and integration of ADR 
reporting into the clinical activities of doctors would almost certainly 
improve reporting. Pharmacovigilance sessions can be developed 
and integrated into clinical activities in the hospital. The sessions can 
be informative and educational, as well as producing feedback and 
accountability for pharmacovigilance activities [33,34]. Sessions and 
other activities that clinicians are able to participate in can be very 
useful in helping to resolve these doubts and misunderstandings. In 
addition, feedback on pharmacovigilance activities is well received 
and appreciated by general practitioners and specialist doctors [35]. 
Doctors may need help with diagnosing ADRs, or in the process of 
recording and reporting ADRs, or obtaining information about 
pharmacovigilance alerts issued by regulatory medicines agencies, or 
any additional information on ADRs. Clinical pharmacologists and 
other pharmacovigilance experts can provide support and assistance to 
physicians in all these areas. 
It is worth stressing that the doctors came up with some interesting 
ideas to enhance and encourage the reporting of ADRs, such as using 
the computing resources within the electronic medical records. 
Several studies have shown that implementing simple strategies such 
as increasing the availability of more yellow cards in health centres, 
including a hyperlink to an online ADR reporting form in hospitals’ 
electronic patient records, regular visits by a clinical expert, or educational 
measures as well as small financial incentives can increase the reporting 
of ADRs [36-42]. ADRs are still discovered by spontaneous reporting 
systems in hospitals, but electronic hospital information systems and 
the implementation of pharmacoepidemiological approaches increase 
the possibilities and the value of ADR detection in hospitals [17]. 
Currently, new powerful and innovative computer systems to detect 
ADRs, based on exploiting clinical data from electronic health care 
records using biomedical computer technologies, are in development, 
which may provide new opportunities for the future development of 
pharmacovigilance activities supplementing the spontaneous reporting 
system [43,44]. In the future, more studies are needed to assess the 
impact of different measures and strategies in order to improve the 
quantity and quality of reporting ADRs. Moreover, doctors made 
proposals to reduce ADRs, such as reviewing drug treatments, and 
withdrawing unnecessary medication. Computerized surveillance has 
proved to be a useful technique in order to understand and prevent 
ADRs, as is the assistance of experts in the drug prescribing process [45-
48]. However, the quality of the implementation process is dependent 
on the physician using the software correctly [49].
Our study has several limitations. The methodology of the study 
was qualitative, and we did not use a structured questionnaire in order 
to collect information in the form of quantitative data. Therefore, we did 
not quantify the number of responses. However, in qualitative studies, 
the content of information (that is expressed in the form of sentences 
that reflects opinions and ideas) is more important than the amount of 
information referred to as a number of responses. It was a study carried 
out in a single centre, albeit a high technology tertiary hospital, where 
we gathered information from doctors representing various medical 
specialities. However, information from other medical specialties, and 
other health professionals like nurses or pharmacists was not collected. 
As well as this, we did not identify or analyse what is happening in the 
primary care facilities. Thus, our results are particularly applicable to 
our institution, but may not apply to other institutions or to primary 
health care. Future studies should look at other areas and centres. 
In conclusion, our study shows that doctors are concerned about 
ADRs, because they believe that ADRs are frequent and relevant 
to their daily clinical practice. There are some doubts about what 
an ADR is, the accuracy of diagnostic methods, the development of 
pharmacovigilance activities and their impact on clinical practice. These 
doubts could be an obstacle to developing pharmacovigilance activities 
in clinical practice. Training in pharmacovigilance and disseminating 
results from pharmacovigilance activities should be developed through 
a closer relationship with hospital doctors, using continuous feedback 
and supporting pharmacovigilance activities.
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